title: Long-term follow-up of contralateral lobe in patients hemithyroidectomized for solitary follicular adenoma.
abstract: OBJECTIVE
  Since there are no available conclusive studies on the long-term evolution of remnant thyroid tissue after hemithyroidectomy in patients who undergo surgery for solitary follicular adenomas, we searched for such cases in our records to elucidate this issue.
  
  
  METHODS
  Search criteria were as follows: (i) presence of a single palpable thyroid nodule with the remainder of the gland normal on palpation; (ii) clinically euthyroid status at the time of surgery; (iii) histological diagnosis of nodule as follicular adenoma; (iv) a hemithyroidectomy operation, sparing the contralateral lobe; (v) normal macroscopic aspect of the contralateral lobe at the time of surgery; and (vi) at least 4 years of postoperative follow-up.
  
  
  METHODS
  Only 47 female cases were found to meet above criteria, with a mean age of 45.9 years (range: 23-79) at the time of surgery and a mean follow-up of 7.2 years (range: 4-32). Besides evaluating the presence or absence of antithyroid antibodies and the extranodular histology of tissue removed during surgery, a preoperative TRH test also allowed patients to be classified into two groups: normal extranodular thyroid (NET) (n = 32) and abnormal extranodular thyroid (AET) (n = 15).
  
  
  RESULTS
  Eleven of the 15 patients with AET had thyroid autoimmunity, with or without overt histological thyroiditis, and the remaining four had subclinical hypothyroidism with negative antithyroid antibody titres. In the entire study population, only 28 patients received treatment with L-T4 immediately after surgery, none of whom had any alterations in the contralateral lobe. However, six of the nineteen patients not treated with T4 (31.6%) developed overt abnormalities in the contralateral lobe, including the only three with AET who had not received L-T4 treatment. The remaining three were two patients with NET, who showed postoperative TSH hyper-responsiveness to TRH (peak TSH > 25 mU/l), and one who developed a new follicular adenoma 32 years later. To date, none of the patients with NET, who had a normal TRH test after surgery, have developed any kind of alterations in the contralateral lobe, even those who received no L-T4 prophylactic treatment.
  
  
  CONCLUSIONS
  The findings of this study suggest that: (i) there is a higher risk of follicular adenomas developing in a gland affected by thyroid autoimmunity than in a previously normal gland; (ii) L-T4 therapy may prevent the formation of new nodules or the development of goitre in the contralateral lobe; and (iii) in the absence of prophylactic treatment after surgery, the contralateral lobe of subjects with thyroid autoimmunity and/or previous subclinical hypothyroidism develops morphological abnormalities.
authors.affiliation: Divisions of Endocrinology and Pathology, Hospital de Clínicas José de San Martín, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina. hniepom@elsitio.net
authors.forename: H
authors.initials: H
authors.lastname: Niepomniszcze
authors.forename: A
authors.initials: A
authors.lastname: Garcia
authors.forename: E
authors.initials: E
authors.lastname: Faure
authors.forename: A
authors.initials: A
authors.lastname: Castellanos
authors.forename: M
authors.initials: M
authors.lastname: del Carmen Zalazar
authors.forename: G
authors.initials: G
authors.lastname: Bur
authors.forename: B
authors.initials: B
authors.lastname: Elsner
mesh_terms: D000236:Adenoma / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007037:Hypothyroidism / Q000150:complications / Q000503:physiopathology; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis; D012307:Risk Factors; D013961:Thyroid Gland / Q000503:physiopathology; D013964:Thyroid Neoplasms / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D013965:Thyroidectomy; D013967:Thyroiditis, Autoimmune / Q000150:complications / Q000503:physiopathology; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000627:therapeutic use*
chemical_list: D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin; D013974:Thyroxine